Results 61 to 70 of about 2,913 (168)

Characterization of pncA Mutations in Pyrazinamide-Resistant Mycobacterium tuberculosis in Brazil [PDF]

Antimicrobial Agents and Chemotherapy, 2005
ABSTRACT In this study the nucleotide sequence of the pncA gene from 59 Mycobacterium tuberculosis clinical isolates was analyzed. Mutations in the pncA gene were identified in 29 of 40 pyrazinamide-resistant isolates, and no pyrazinamidase activity was ...
Vívian de F Sumnienski, Rodrigues, Maria Alice, Telles, Marta Osório, Ribeiro, Patrícia Izquierdo, Cafrune, Maria Lucia Rosa, Rossetti, Arnaldo, Zaha   +5 more
openaire   +3 more sources

Development and Validation of an Algorithm to Identify Prenatal Care in Administrative Data: Predictive Validity for Adverse Birth Outcomes

Health Services Research, Volume 61, Issue 1, February 2026.
ABSTRACTObjectiveTo develop and validate a hierarchical algorithm for assigning prenatal care (PNC) encounters using claims data while ensuring continuity of care.Study Setting and DesignWe conducted a retrospective cohort study among South Carolina Medicaid beneficiaries.
Songyuan Deng, Greg Barabell, Kevin J. Bennett   +2 more
wiley   +1 more source

Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method. [PDF]

PLoS ONE, 2011
Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug. But PZA susceptibility test is challenging because PZA activity is optimal only in an acid environment that inhibits the growth of M. tuberculosis.
Man Zhou, Xuelei Geng, Jun Chen, Xude Wang, Dianbing Wang, Jiaoyu Deng, Zhiping Zhang, Weihua Wang, Xian-En Zhang, Hongping Wei   +9 more
doaj   +1 more source

Tie2‐Dependent Mechanisms Influence Leptomeningeal Collateral Dynamics and Reperfusion Following Stroke

Advanced Science, Volume 13, Issue 3, 14 January 2026.
This work demonstrates that endothelial EphA4 limits Tie2 activation and curbs leptomeningeal collateral expansion after ischemic stroke. Pharmacological activation of Tie2 by an Ang‐1 mimetic or genetic loss of EphA4 stimulates collateral vessel growth, improves cerebral perfusion, and enhances neurological recovery.
Alexandra M. Kaloss, Caroline de Jager, Kennedie Lyles, Nathalie A. Groot, Jackie Zhu, Yu Lin, Michael Chen, Hehuang Xie, John B. Matson, Michelle H. Theus   +9 more
wiley   +1 more source

Evaluation of Xpert MTB/XDR and Deeplex Myc‐TB for the Rapid Detection of Drug Resistance in Mycobacterium tuberculosis

International Journal of Microbiology, Volume 2026, Issue 1, 2026.
Objectives Rapid identification of drug‐resistant tuberculosis remains critical for the initiation of appropriate treatment regimens, improved success rates and reduction in the development of drug resistance. In this study, we compared the diagnostic performance of two novel diagnostic tests, Xpert MTB/XDR and Deeplex Myc‐TB (both CE marked).
Mirae Park, Priya Solanki, Timothy Daniel McHugh, Onn Min Kon, Giovanni Satta, Esha Saini   +5 more
wiley   +1 more source

Detection of Pyrazinamide Resisitance in Mycobacterium Tuberculosis by Sequencing of pncA Gene

Tuberculosis and Respiratory Diseases, 2001
Background : Examining the biological susceptibility of Mycobacterium tuberculosis to pyrazinamide (PZA) in vitro is very difficult as PZA is inactive under normal culture conditions. The biological susceptibility test, an enzyme assay for Pzase activity, and a genetic test for pncA gene mutations, were performed in order to predict PZA resistance ...
Jee Yoon Hwang, Kyung Rok Kwak, Hye Kyung Park, Ji Seok Lee, Sam Seok Park, Yun Seong Kim, Jung Yoo Lee, Chul Hun Chang, Min Ki Lee, Soon Kew Park   +9 more
openaire   +1 more source

Non- pncA Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That? [PDF]

Journal of Clinical Microbiology, 2017
ABSTRACT Pyrazinamide (PZA) is a key component for the effective treatment of drug-susceptible and PZA-susceptible multidrug-resistant (MDR PZA-S ) tuberculosis (TB). pncA gene mutations are usually detected in a clear majority (>90%) of PZA-resistant strains but obviously not in
Jim, Werngren, Erik, Alm, Mikael, Mansjö   +2 more
openaire   +2 more sources

Combating Drug‐Resistant Tuberculosis: Advancements in Diagnostics and Therapeutics

Pulmonary Medicine, Volume 2026, Issue 1, 2026.
The increasing prevalence of multidrug‐resistant (MDR) and extensively drug‐resistant (XDR)Mycobacterium tuberculosis has emerged as a major global health concern. Advanced molecular diagnostics, including rapid assays, have improved resistance detection; however, resource‐limited settings remain underserved. Nanotechnology‐based drug delivery systems,
Silvi Gautam, Jahanvi Saini, Shabaaz Begum Jameel Pasha, Divakar Sharma, Divya Venugopal, Semonti Nandi   +5 more
wiley   +1 more source

Silibinin‐driven microbial and metabolic reprogramming restores CD4+ T cell immunity in HIV immunological nonresponders

VIEW, Volume 6, Issue 6, December 2025.
Despite efficacious antiretroviral therapy, 10%–40% of HIV‐infected individuals exhibit inadequate immune reconstitution due to persistent inflammatory activation and NAD+ metabolic dysregulation—a critical cofactor in cellular bioenergetics. We administered silibinin to 53 HIV immunological non‐responders and elucidated its mechanism through selective
Wenli Liu, Minghui An, Qi Wang, Yuxin Shang, Shuyao Zang, Haibo Ding, Shuai Fu, Yun Liu, Xue Dong, Xiao Yang, Jinna Dai, Xiaoxu Han, Yingchun Xu, Hong Shang   +13 more
wiley   +1 more source

Characterization ofpncAMutations of Pyrazinamide-ResistantMycobacterium tuberculosisin Korea [PDF]

Journal of Korean Medical Science, 2001
Pyrazinamide (PZA) is one of the most important drugs for the treatment of Mycobacterium tuberculosis infection. However, the increasing frequency of PZA-resistant strains limits its effectiveness. In Korea, most PZA-resistant strains also exhibit both isoniazid and rifampin resistance making it essential to identify these resistant strains accurately ...
K W, Lee, J M, Lee, K S, Jung
openaire   +2 more sources